Microba appoints Therapeutics Head

    • Appointment of Professor Trent Munro as Senior Vice President of Therapeutics.
    • Professor Munro has over 25 years’ research and development experience, including with multinational biopharmaceutical company Amgen based in California, United States.
    • Professor Munro has recently held several leadership roles in Australia including Director of the National Biologics Facility (NBF), Program Director of the CEPI funded Rapid Response Vaccine pipeline and Director of the ARC Centre for Biopharmaceutical Innovation (CBI).

    Subscribe to our Telegram channel to get a daily dose of business and lifestyle news from NHA – News Hub Asia!

    Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce Professor Trent Munro will be joining the company as Senior Vice President of Therapeutics. Professor Munro has over 25 years’ research and development experience, including with multinational biopharmaceutical company Amgen.

    Commenting on the appointment, Chief Executive Officer Dr Luke Reid said, “As the company enters into clinical trials, Professor Munro brings significant pharmaceutical and US drug development experience to advance our therapeutic programs and establish partnerships with large pharmaceutical companies.”

    Professor Trent Munro commences employment with Microba today, Wednesday, April 6, and will be leading the Company’s therapeutic strategy to progress its valuable drug development programs and pharma partnering engagements.

    Source: Microba Life Sciences Limited(Press release)